CYP2C19 and acute coronary syndrome: Evidence on the utility of CYP2C19 point-of-care (POC) testing to guide antiplatelet therapy selection in patients with acute coronary syndrome (ACS) or stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) is currently limited.